
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is poised for growth and diversification in various markets and their continuous innovation and strong partnerships with healthcare providers give them a competitive edge. Additionally, their strong financial performance, with a current P/E ratio of 48.26, indicates a positive outlook for investors. However, potential risks such as regulatory delays and competition in the medical device industry should be carefully monitored. Overall, Edwards Lifesciences' impressive track record and promising future make it a solid investment choice for long-term growth.
Bears say
Edwards Lifesciences is a leader in advanced structural heart disease technologies, with an established portfolio of successful products. However, potential risks include competition from new market entrants and innovation from existing competitors, as well as potential delays in regulatory approvals or clinical trials. Furthermore, changing market dynamics and negative clinical data could affect the company's growth potential and profitability.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares